Eli Lilly Stock Slides 5% on Obesity Drug Market Warning

Edgen Stock·Mar 17 2026, 16:34

Share to

Share to

Copy link

Key Takeaways

Eli Lilly's stock is under pressure after an HSBC downgrade questioned the high valuation of the obesity drug market. This contrasts with broader analyst bullishness but reflects growing investor concerns about competition and market saturation, a sentiment increasingly visible in the options market.

Eli Lilly's stock fell 5% on March 18, driven by an HSBC downgrade to "reduce" over concerns of an "inflated market" for obesity drugs.
The downgrade conflicts with broad consensus, where 26 of 30 analysts maintain "buy" ratings and a consensus target price of $1,201.43 suggests a 21.5% premium.
Options traders are increasingly bearish, with a key put/call volume ratio climbing to a level higher than 98% of readings over the past year.

HSBC Downgrade Cites "Inflated Market" for 5% Stock Drop

Eli Lilly (NYSE: LLY) shares fell 5% on March 18, deepening a recent downtrend after a significant analyst downgrade. HSBC cut its rating on the pharmaceutical giant to "reduce" from "hold," directly citing an "inflated market" for obesity drugs and stating that the company's current valuation is appropriate. This move sent the stock to trade around $967, reflecting investor anxiety over the sustainability of the sector's rapid growth.

Analyst Consensus Remains Bullish Despite Warning Signs

HSBC's bearish note stands in stark contrast to the overwhelmingly positive sentiment from the broader analyst community. Prior to the downgrade, 26 of the 30 firms covering Eli Lilly held "buy" or stronger ratings. The 12-month consensus price target of $1,201.43 implies a potential 21.5% upside from current trading levels, signaling that most of Wall Street still anticipates significant growth. However, the stock has taken a breather from its January 8 record high of $1,133.95 and is down 9.8% year-to-date, though it has found technical support at the $950 price level.

Options Market Prices in Further Declines

Derivatives traders appear to be aligning with the more cautious outlook. Eli Lilly's 10-day put/call volume ratio climbed to 1.16, a reading higher than 98% of all observations over the past year. This metric shows a strong preference for puts, which are bets on a price decline, over calls. Reinforcing this sentiment, the stock's put/call open interest ratio of 1.60 ranks higher than all other readings from the past 12 months, indicating a sustained buildup of bearish positions as competition in the GLP-1 drug market intensifies with rivals like Novo Nordisk.